The company said last month that a recent-stage study on Avigan showed reduced recovery times for Covid-19 patients with mild symptoms, and that it would seek to apply for regulatory approval this month at the earliest.
The company’s shares jumped nearly 3 percent on the news.
The study of 156 patients in Japan showed that those treated with Avigan improved after 11.9 days, compared with 14.7 days for patients who took a placebo.
Afihan, also known as favipiravir, is approved in Japan as a flu medicine. It is currently undergoing at least 16 clinical trials around the world, but there are still concerns about the drug after animal studies showed that it causes birth defects in babies.
These were the details of the news Japanese Fujifilm shares rise 3% after requesting approval to use Avigan... for this day. We hope that we have succeeded by giving you the full details and information. To follow all our news, you can subscribe to the alerts system or to one of our different systems to provide you with all that is new.
It is also worth noting that the original news has been published and is available at saudi24news and the editorial team at AlKhaleej Today has confirmed it and it has been modified, and it may have been completely transferred or quoted from it and you can read and follow this news from its main source.
